Search
AGA2115
go.drugbank.com/drugs/DB17840InvestigationalDeveloped by Angitia Biopharmaceuticals, AGA2115 is being investigated for the treatment of osteogenesis imperfect.[L46646]
LY2275796
go.drugbank.com/drugs/DB05165InvestigationalLY2275796 is a second-generation antisense anti-cancer drug candidate for clinical development.
Mavelertinib
go.drugbank.com/drugs/DB16228InvestigationalMavelertinib is under investigation in clinical trial NCT02349633 (Study for Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)).
Petrelintide
go.drugbank.com/drugs/DB19442InvestigationalPetrelintide is under investigation in clinical trial NCT06662539 (Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities).
VLTS-934
go.drugbank.com/drugs/DB05597InvestigationalVLTS-934 was developed by Valentis inc. for the treatment of Peripheral Arterial Disease (PAD).
RAPA-501-Allo
go.drugbank.com/drugs/DB15890InvestigationalRAPA-501-ALLO is composed of T-cells extracted from healthy volunteers; these cells are then reprogrammed _ex vivo_ in a process that involves de-differentiation and re-differentiation.[L16483]
Modipafant
go.drugbank.com/drugs/DB16237InvestigationalModipafant is under investigation in clinical trial NCT02569827 (Celgosivir or Modipafant as Treatment for Adult Participants With Uncomplicated Dengue Fever in Singapore).
Edrophonium
go.drugbank.com/drugs/DB01010ApprovedA rapid-onset, short-acting cholinesterase inhibitor used in cardiac arrhythmias and in the diagnosis of myasthenia gravis. It has also been used as an antidote to curare principles.
Categories: Compounds used in a research, industrial, or household settingBW-A 58C
go.drugbank.com/drugs/DB06740Experimentala 54 kDa CYP2C9 form of cytochrome P450, P450hB20-27. … naphthoquinone antimalarial drug which undergoes extensive alkyl hydroxylation to a single t-butylhydroxy metabolite in man in vivo and also in human liver microsomes, where this is catalysed primarily by
ARX201
go.drugbank.com/drugs/DB05082InvestigationalARX201 (PEG-ahGH) is a recombinant form of human growth hormone that has been modified using Ambrx’s patented ReCODE™ technology to achieve precise spatial positioning of the site of polyethylene glycol … (PEG) attachment to human growth hormone, by biosynthetic incorporation of a chemically unique amino acid (ahGH).